Jefferies Group's CHRS Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 252,000 shares of Coherus Oncology, Inc. (CHRS) worth $425,880, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in CHRS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 113,000 shares. Largest reduction occurred in Q1 2026, reducing 143,190 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Coherus Oncology (CHRS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Coherus Oncology (CHRS) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -143,190 | Reduce 36.23% | 252,000 | $1.69 |
| Q4 2025 | +69,565 | Add 21.36% | 395,190 | $1.42 |
| Q3 2025 | +8,000 | Add 2.52% | 325,625 | $1.64 |
| Q1 2025 | +10,000 | Add 3.25% | 317,625 | $0.81 |
| Q4 2024 | +25,000 | Add 8.85% | 307,625 | $1.38 |
| Q3 2024 | +86,000 | Add 43.74% | 282,625 | $1.04 |
| Q1 2024 | +113,000 | Add 135.13% | 196,625 | $2.39 |
| Q4 2023 | +43,000 | Add 105.85% | 83,625 | $3.33 |
| Q3 2023 | +40,625 | New Buy | 40,625 | $3.74 |
| Q2 2023 | -130,625 | Sold Out | 0 | $0.00 |
| Q1 2023 | +106,000 | Add 430.46% | 130,625 | $6.84 |
| Q4 2022 | +24,625 | New Buy | 24,625 | $7.92 |
Jefferies Group's Coherus Oncology Investment FAQs
Jefferies Group first purchased Coherus Oncology, Inc. (CHRS) in Q4 2022, acquiring 24,625 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Coherus Oncology, Inc. (CHRS) for 14 quarters since Q4 2022.
Jefferies Group's largest addition to Coherus Oncology, Inc. (CHRS) was in Q1 2024, adding 196,625 shares worth $469,934.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 252,000 shares of Coherus Oncology, Inc. (CHRS), valued at approximately $425,880.
As of the Q1 2026 filing, Coherus Oncology, Inc. (CHRS) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Coherus Oncology, Inc. (CHRS) was 395,190 shares, as reported at the end of Q4 2025.